Thyroid cancer (TC) is the most common endocrine malignancy. Recurrence or tumour metastasis remains a major challenge in the treatment of thyroid cancer. At Alfa Cytology, our team of experienced biologists work with you to develop thyroid cancer therapeutics.
Introduction to Thyroid Cancer
Rising prevalence of thyroid cancer in the U.S. is driving the growth of the thyroid cancer drugs market. North America held the highest market share in the thyroid cancer drugs market and is expected to continue to grow throughout the forecast period due to the rising prevalence of thyroid cancer cases in the region. In the U.S., thyroid cancer is the 13th most common cancer and is expected to account for nearly 44,000 new cases in 2022, accounting for approximately 2.3% of all cancer diagnoses. Among women, it is the sixth most common cancer.
Current Therapies for Thyroid Cancer
The thyroid cancer drugs market was valued at around USD 833.84 Million in 2024. The thyroid cancer drugs market is estimated to grow at a CAGR of 17.02% during the forecast period. Pharmaceutical companies are currently developing new drugs, particularly targeted therapies for the treatment of advanced thyroid cancer. These innovative drugs represent a major advance on existing therapies, allowing for more precise targeting of cancer cells while potentially minimising side effects.
Some of the key players leading in the market include:
- Mylan N.V.
- Bristol-Myers Squibb Company
- Teva Pharmaceutical Industries Ltd
- Jerome Stevens Pharmaceuticals, Inc
- Baxter
- Abbott
- Celgene Corporation
- AstraZeneca
- GlaxoSmithKline plc
- others
Ongoing Clinical Trials in Thyroid Cancer
These are just a few examples of the many ongoing clinical trials exploring targeted inhibitor therapies in various subtypes and genetic contexts of thyroid cancer.
| Recruiting |
Phase |
Target |
| Anlotinib hydrochloride |
|
VEGFR, PDGFR, FGFR, and c-kit |
| Selpercatinib |
|
RET |
| Imatinib |
|
PDGFRα |
| Trametinib |
|
MEK1, MEK2 |
| HA121-28 Tablets |
|
EGFR/RET |
As our understanding of the molecular drivers of TC continues to evolve, the development of more personalized, targeted treatment approaches remains an active area of investigation.
Our Services
This surge in market size underscores the increasing demand for effective and innovative therapy solutions. As a leading preclinical contract research organization (CRO), Alfa Cytology has established a strong reputation for its expertise in thyroid cancer research. The company's multidisciplinary team of scientists and regulatory specialists collaborate seamlessly to provide comprehensive and tailored solutions for clients in the pharmaceutical and biotechnology industries.
By collaborating with Alfa Cytology, clients gain access to a comprehensive suite of services tailored to the unique needs of thyroid cancer research and development. From preclinical study design and execution to data analysis, the company's team of experts is dedicated to empowering clients' efforts in bringing transformative thyroid cancer therapies to market. If you are interested in our service, please contact us.
! For research use only.
Related Services
